Brind.
  1. Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.
  2. Sanofi, Regeneron, and Bayer are involved in new market developments, including FDA submissions regarding eczema and eye care treatments.
  3. Regeneron, Bayer, and FDA are involved in the joint development of Eylea HD, following an FDA inspection of a third-party manufacturer.

Regeneron recorded net product sales of Eylea in the US, and Bayer confirmed its collaboration on the drug's development.

1 report, 1 independent Updated Jul 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Regeneron recorded net product sales of Eylea in the US, and Bayer confirmed its collaboration on the drug's development.

Who's involved

What this event is mainly about
BAYERRegeneron Pharmaceuticals

Keep exploring

Part of

Regeneron, Bayer, and FDA are involved in the joint development of Eylea HD, following an FDA inspection of a third-party manufacturer.

Also in this story

All 3 developments

Within Major pharmaceutical companies including Sanofi, Regeneron, Roche, Eli Lilly, Biogen, and Gilead are maintaining alliances and competing across key therapeutic areas like ophthalmology, immunology, and oncology.

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksREGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth? Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. (REGN) r